Difference between revisions of "Sevoflurane"
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | == | + | {{unfinished}} |
| + | {{toplink | ||
| + | |linkpage =Anaesthesia | ||
| + | |linktext =Anaesthesia | ||
| + | |maplink= Anaesthesia Content Map - WikiClinical | ||
| + | |sublink1=Anaesthetic Drugs | ||
| + | |subtext1=Anaesthetic Drugs | ||
| + | |sublink2=Inhalation Agents | ||
| + | |subtext2=Inhalation Agents | ||
| + | |pagetype=Clinical | ||
| + | }} | ||
| + | <br> | ||
'''Sevoflurane''' is very similar to [[Isoflurane|isoflurane]] but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can also be used as a maintentance agent. It is becoming more popular in veterinary anaesthesia. | '''Sevoflurane''' is very similar to [[Isoflurane|isoflurane]] but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can also be used as a maintentance agent. It is becoming more popular in veterinary anaesthesia. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
| − | Sevoflurane is also a halogenated ether. It is also stable and nonflammable. Alkaline carbon dioxide absorbents react with sevoflurane to produced a potentially toxic compound. This can be influenced by environmental temperature, sevoflurane concentrations, use of baralyme rather then sodalime, low flow rates and already exposed absorbents. The '''blood:gas partition coefficient''' is very low, meaning that has a rapid onset of action. It has a high tissue solubility however, which means that recovery is more prolonged compared to [[Isoflurane|isoflurane]] or [[Halothane|halothane]]. The '''MAC''' of sevoflurane is approximately ''2.4%'' in dogs and ''2.6%'' in cats and is therefore less potent | + | Sevoflurane is also a halogenated ether. It is also stable and nonflammable. Alkaline carbon dioxide absorbents react with sevoflurane to produced a potentially toxic compound. This can be influenced by environmental temperature, sevoflurane concentrations, use of baralyme rather then sodalime, low flow rates and already exposed absorbents. The '''blood:gas partition coefficient''' is very low, meaning that has a rapid onset of action. It has a high tissue solubility however, which means that recovery is more prolonged compared to [[Isoflurane|isoflurane]] or [[Halothane|halothane]]. The '''MAC''' of sevoflurane is approximately ''2.4%'' in dogs and ''2.6%'' in cats and is therefore less potent the other agents. Sevoflurane undergoes a small amount of hepatic metabolism. |
==Adverse Effects== | ==Adverse Effects== | ||
| Line 18: | Line 29: | ||
==Contraindications== | ==Contraindications== | ||
*It is advisable to avoid the use of sevoflurane in patients with renal disease as there is a potential for further renal damage. | *It is advisable to avoid the use of sevoflurane in patients with renal disease as there is a potential for further renal damage. | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Revision as of 16:44, 1 September 2009
 |
This article is still under construction. |
|
Sevoflurane is very similar to isoflurane but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can also be used as a maintentance agent. It is becoming more popular in veterinary anaesthesia.
Pharmacokinetics
Sevoflurane is also a halogenated ether. It is also stable and nonflammable. Alkaline carbon dioxide absorbents react with sevoflurane to produced a potentially toxic compound. This can be influenced by environmental temperature, sevoflurane concentrations, use of baralyme rather then sodalime, low flow rates and already exposed absorbents. The blood:gas partition coefficient is very low, meaning that has a rapid onset of action. It has a high tissue solubility however, which means that recovery is more prolonged compared to isoflurane or halothane. The MAC of sevoflurane is approximately 2.4% in dogs and 2.6% in cats and is therefore less potent the other agents. Sevoflurane undergoes a small amount of hepatic metabolism.
Adverse Effects
Central Nervous System
- Increases intracranial pressure due to cerebral vasodilation.
Cardiovascular System
- Mild myocardial contractility depression.
- Decreased arterial blood pressure and systemic vascular resistance.
Other Systems
- There is an increase in hepatic artery flow, but reduced in the hepatic portal vein, like isoflurane.
Contraindications
- It is advisable to avoid the use of sevoflurane in patients with renal disease as there is a potential for further renal damage.